Drugs / Zenocutuzumab
Zenocutuzumab
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05588609 | Nov 2022 → Jul 2025 | castration-resistant prostate carcinoma | Partner Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03321981 | Jan 2018 → Oct 2022 | breast carcinoma | Merus B.V. | Completed | No outcome recorded |
| Phase 2 | NCT02912949 | Jan 2015 → Dec 2026 expected | — | Partner Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04100694 Background | — | breast cancer, cancer of unknown primary site, cholangiocarcinoma, colorectal cancer +5 | Merus B.V. | Approved for marketing | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zenocutuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03321981 ↗ |
| Known as | Bizengri | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298025 ↗ |
| Known as | MCLA-128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05588609 ↗ |
| Known as | Zeno | “Zenocutuzumab, or Zeno, is a treatment that is being tested to see if it can stop cancer that is growing because of NRG1 gene fusions.” PMID 38348690 ↗ Feb 2024 |
| Known as | Zenocutuzumab-zbco | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298025 ↗ |
| Action | Inhibit | “inhibits NRG1 binding” PMID 38348690 ↗ Feb 2024 |
| Modality | Monoclonal antibody | “HER2/HER3 bispecific antibody” NCT04100694 ↗ |
| Route | Intravenous | “750 mg intravenously every 2 weeks” PMID 39908431 ↗ Feb 2025 |